236 
Market Cap
Stock Chart
Alchemia - 30 Day Poll
Recent BLOGS About Alchemia Add New
Latest Company News
|
Political uncertainty forces a CO2 rethink
The Australian - May 14, 2012 CRITERION'S preconceived line on the carbon abatement group's modest but promising first-half earnings ($1.6 million on revenue of $32m ) were about CO2 benefiting as corporates position for the carbon-tax regime from July 1.
|
|
Alchemia gaining US share for anticoagulant
Australian Life Scientist - May 14, 2012 US sales of generic fondaparinux, the anticoagulant produced by Alchemia (ASX:ACL), are expected to have grown 120% year-on-year. Alchemia's (ASX:ACL) anti-coagulant product, generic fondaparinux, is gaining US market share due to sales efforts of ...
|
|
Alchemia Limited Announces Grant Of US Pater For Fondaparinux Manufacturing Process
Reuters Key Development - Feb 28, 2012 |
|
Alchemia Limited Announces Capital Raising; Proposes De-Merger Of Alchemia Oncology Pty Ltd
Reuters Key Development - Nov 6, 2011 |
|
Alchemia Limited Announces Initiation Of Phase II Trial In Small Cell Lung Cancer
Reuters Key Development - Sep 12, 2011 |
Website
Videos related to Alchemia
Company Profile
Alchemia is a biotechnology company with particular expertise in chemistry. They have one product approved and being marked - synthetic heparin.
Consolidated cash position was approx. $21.4 million in December 2011
Operating expenditure of $6.5 million
Upcoming Events:
- Phase III colorectal cancer trial
- Phase II cancer stem cell program
Highlights:
- revenues for synthetic Heparin have begun
- Positive results for colorectal cancer Phase II trial
- the HyACTdrug delivery platform Alchemia's antithrombotic drug, generic heparin, is the Company's primary opportunity and targets the multi-billion dollar heparin-drug market with Fondaparinux.
Fondaparinux is may have a superior safety and efficacy relative to the market leading drug Lovenoxand. Alchemia's product is very difficult to synthesize and therefore it is possible that there will be limited competition from other generics. For this drug ACL earns a 50-60% share of profits from Dr Reddy’s, equating to a 30-35% effective royalty rate (RBS Morgans estimate). In Feb 2012, the Company reported that Dr Reddy’s had established a market share of 18% by number of prescriptions with weekly sales in excess of US $1.4m (Source: IMS; Bloomberg/Wolters Kluwer). Since then, an upward trend has continued, and the Directors reiterate their confidence that the Company is on track to meet its expectations for fondaparinux in 2012.
HA-irinotecan is Alchemia's most advanced anticancer product. It HA-irinotecan not only allowed more cycles of irinotecan to be administered to colon cancer patients, but also produced significant disease control and a doubling in progression free survival.
The HyACTdrug delivery platform presents multiple product opportunities. HyACTimproves the delivery of chemotherapeutic agents to cancer cells. HyACTboosts drug efficacy and reduces unwanted side effects. The technology also has applications and is applicable to other therapeutic agents from small molecule cytotoxics to much larger biologics (i.e. monoclonal antibodies).
Possible Competitors
Apicore LLC has filed for a possible equivalent generic heparin with the FDA